Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
05 déc. 2019 08h15 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor...
Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results
07 nov. 2019 16h01 HE
|
Zogenix, Inc.
Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis...
Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7
31 oct. 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome
25 oct. 2019 09h00 HE
|
Zogenix, Inc.
Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction...
Zogenix Completes Acquisition of Modis Therapeutics, Inc.
09 sept. 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully...
Zogenix Announces Acquisition of Modis Therapeutics, Inc.
26 août 2019 07h00 HE
|
Zogenix, Inc.
Advances Zogenix’s strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting...
Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome
08 juil. 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed...
Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
27 juin 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final...
Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results
08 mai 2019 16h01 HE
|
Zogenix, Inc.
Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early JuneFINTEPLA Dravet syndrome MAA accepted for review by EMAExclusive distribution...
Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
07 mai 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D.,...